(Q28279556)

4

0 references

Stefano Moro

object named as

Stefano Moro

5

0 references

author name string

Gloria Cristalli

1

0 references

Barbara Cacciari

2

0 references

Giampiero Spalluto

6

0 references

Rosaria Volpini

The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart

7

0 references

language of work or name

English

0 references

publication date

March 2007

0 references

published in

ChemMedChem

0 references

volume

2

0 references

issue

3

0 references

page(s)

260-81

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A2a selective adenosine receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

Medicinal chemistry and pharmacology of A2B adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine receptors as therapeutic targets

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Pharmacology of adenosine A2A receptors and therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

RDC8 codes for an adenosine A2 receptor with physiological constitutive activity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Molecular cloning of a novel adenosine receptor gene from rat brain.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Molecular characterization of a human brain adenosine A2 receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Cloning and expression of the A2a adenosine receptor from guinea pig brain.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Inosine potentiation of the effect of adenosine on the heart

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine deaminase: functional implications and different classes of inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-(Alkylthio)adenosines, specific coronary vasodilators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis and coronary vasodilating activity of 2-substituted adenosines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Medicinal chemistry of adenosine A2A receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Inhibition of platelet aggregation by adenosine receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Deaza analogues of adenosine as inhibitors of blood platelet aggregation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

5'-Deoxy-5'-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

N6-substituted adenosine receptor agonists: potential antihypertensive agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

The antihypertensive effect of 2-alkynyladenosines and their selective affinity for adenosine A2 receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Nucleosides and nucleotides. 107. 2-(Cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structure-activity relationships for N6-substituted adenosines at a brain A1-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

The synthesis and biological activity of a highly selective adenosine A2a receptor agonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Dog coronary artery adenosine receptor: structure of the N6-aryl subregion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Correlation of adenosine receptor affinities and cardiovascular activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-(N'-aralkylidenehydrazino)adenosines: potent and selective coronary vasodilators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Ribose-Modified Adenosine Analogs as Potential Partial Agonists for the Adenosine Receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Effects of several 5?-carboxamide derivatives of adenosine on adenosine receptors of human platelets and rat fat cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

C2,N6-disubstituted adenosines: synthesis and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis of di- and tri-substituted adenosine derivatives and their affinities at human adenosine receptor subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-substituted thioadenine nucleoside and nucleotide analogues: synthesis and receptor subtype binding affinities (1).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Efficient synthesis of an adenosine A2a agonist: glycosylation of 2-haloadenines and an N2-alkyl-6-chloroguanine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-Phenylhydroxypropynyladenosine derivatives as high potent agonists at A2B adenosine receptor subtype

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

A2B adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyl adenosine and NECA derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-substituted 5'-N-methylcarboxamidoadenosine (MECA) derivatives as A3 adenosine receptor ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Design, synthesis, and evaluation of novel A2A adenosine receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis of New Nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives ofN-methyl-D-ribofuranuronamide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

The role of receptor structure in determining adenosine receptor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Medicinal chemistry of A2A adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Progress in the pursuit of therapeutic adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Antinociceptive effects of novel A2B adenosine receptor antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

(E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists: Influence of the Chain at the N8Pyrazole Nitrogen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent A(2A) adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo [4,3-alpha]-quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis and evaluation of 7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines as potential A2A adenosine receptor antagonists for positron emission tomography (PET).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

New adenosine A2A receptor antagonists: actions on Parkinson's disease models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

1-Phenylpyrazolo[3,4-d]pyrimidines; structure-ac:tivity relationships for C6 substituents at A1 and A2A adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis and SAR evaluation of 1,2,4-triazoles as A(2A) receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Crystal structure of rhodopsin: A G protein-coupled receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

A2B adenosine receptor antagonists: recent developments

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

G protein-coupled receptors as challenging druggable targets: insights from in silico studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Molecular modeling studies of human A3 adenosine antagonists: structural homology and receptor docking

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Identification of a receptor/G-protein contact site critical for signaling specificity and G-protein activation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Cloned receptors and cardiovascular responses to adenosine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Selective attenuation by N-0861 (N6-endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptor-mediated effects in humans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

The future of pharmacologic stress: selective A2A adenosine receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

A comparison of adenosine A2A agonism and methylprednisolone in attenuating neuronal damage and improving functional outcome after experimental traumatic spinal cord injury in rabbits

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine A2A receptor activation reduces lung injury in trauma/hemorrhagic shock

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

2-(1-Hexyn-1-yl)adenosine-induced intraocular hypertension is mediated via K+ channel opening through adenosine A2A receptor in rabbits

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

An adenosine A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine, neurodegeneration and neuroprotection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Adenosine receptor agonists: from basic medicinal chemistry to clinical development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021

Pathophysiology and therapeutic potential of purinergic signaling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600193

7 January 2021